This trial will study whether it's safe to forgo radiation treatment after lumpectomy surgery for postmenopausal women with hormone-positive, Her2-negative tumors who have a low risk of cancer recurrence.
1 Primary · 0 Secondary · Reporting Duration: 5 years of follow up
202 Total Participants · 1 Treatment Group
Primary Treatment: endocrine therapy alone without radiotherapy · No Placebo Group · N/A
Age 50 - 69 · Female Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: